Suppliers and packagers for generic pharmaceutical drug: OXYBUTYNIN CHLORIDE

OXYBUTYNIN CHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Chartwell Rx	OXYBUTYNIN CHLORIDE	oxybutynin chloride	SYRUP;ORAL	075039	ANDA	Chartwell RX, LLC	62135-520-24	2 TRAY in 1 BOX (62135-520-24) / 10 CUP in 1 TRAY / 5 mL in 1 CUP (62135-520-05)	1999-01-29
Chartwell Rx	OXYBUTYNIN CHLORIDE	oxybutynin chloride	SYRUP;ORAL	075039	ANDA	Chartwell RX, LLC	62135-520-47	473 mL in 1 BOTTLE (62135-520-47)	1999-01-29
Chartwell Rx	OXYBUTYNIN CHLORIDE	oxybutynin chloride	SYRUP;ORAL	075039	ANDA	Chartwell Governmental & Specialty RX, LLC.	68999-520-24	2 TRAY in 1 BOX (68999-520-24) / 10 CUP in 1 TRAY / 5 mL in 1 CUP (68999-520-05)	1999-01-29

Oxybutynin Chloride: Key Suppliers and Patent Landscape

Last updated: February 19, 2026

This report analyzes the current supply landscape and patent protection for oxybutynin chloride, a widely used antimuscarinic agent for treating urinary incontinence. Key suppliers are identified, alongside an overview of active patent filings and their implications for market entry and competition.

Who Are the Primary Manufacturers of Oxybutynin Chloride API?

The global supply of oxybutynin chloride active pharmaceutical ingredient (API) is concentrated among a select group of manufacturers, primarily in Asia. These suppliers are critical for generic drug producers and brand-name manufacturers.

• Major Suppliers Identified:
  • Zhejiang NHU Co., Ltd. (China): A significant producer of various APIs, including oxybutynin chloride. The company operates state-of-the-art facilities and adheres to international quality standards.
  • Lianyungang Oriental Pharmaceutical Co., Ltd. (China): Another key player in the Chinese API market, Lianyungang Oriental Pharmaceutical manufactures oxybutynin chloride for both domestic and international markets.
  • Prism Pharma Co., Ltd. (India): Prism Pharma is a notable Indian manufacturer with a strong presence in the generic API sector, including oxybutynin chloride.
  • Aurobindo Pharma Ltd. (India): A large, integrated pharmaceutical company, Aurobindo Pharma supplies a broad range of APIs, with oxybutynin chloride being among its offerings.
  • Sun Pharmaceutical Industries Ltd. (India): As one of the largest pharmaceutical companies globally, Sun Pharma is a significant supplier of APIs, including oxybutynin chloride, catering to diverse market needs.
  • Dr. Reddy's Laboratories Ltd. (India): Another major Indian pharmaceutical firm, Dr. Reddy's Laboratories produces and supplies oxybutynin chloride API.

These manufacturers typically hold accreditations from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), enabling them to supply products to regulated markets.

What is the Patent Protection Status for Oxybutynin Chloride?

Oxybutynin chloride itself is an old drug, and its primary composition of matter patents have long expired. However, patent protection in the pharmaceutical sector extends beyond the core molecule to include various aspects of its development, formulation, manufacturing processes, and new therapeutic uses.

• Expired Core Patents: The original patents covering the oxybutynin molecule have expired, allowing for generic production.
• Formulation Patents: Innovation has focused on developing improved delivery systems and formulations to enhance efficacy, reduce side effects, or improve patient compliance.
  • Extended-Release Formulations: Several patents cover extended-release versions of oxybutynin chloride. These aim to provide smoother drug delivery and reduce peak-and-trough concentrations associated with immediate-release formulations, thereby potentially minimizing anticholinergic side effects like dry mouth and blurred vision. Examples include formulations designed for once-daily dosing.
  • Transdermal Patches: Patents exist for transdermal delivery systems of oxybutynin chloride. These systems offer an alternative route of administration, bypassing first-pass metabolism and potentially providing more consistent drug levels and reduced gastrointestinal side effects.
• Manufacturing Process Patents: Companies may patent novel or improved methods for synthesizing oxybutynin chloride API or its intermediates. These patents can provide a competitive advantage by offering more efficient, cost-effective, or environmentally friendly production routes.
• Method of Use Patents: While the primary indication for oxybutynin chloride is overactive bladder, patents may cover its use in treating other conditions, or specific patient populations, where its antimuscarinic properties could be beneficial.

Active Patent Filings and Their Implications

A review of patent databases reveals ongoing filings related to oxybutynin chloride, primarily in the areas of new formulations and manufacturing improvements.

• Recent Filing Trends:

  • Novel Excipient Combinations: Filings often detail specific combinations of excipients (inactive ingredients) designed to control drug release kinetics in extended-release formulations. These patents can be highly specific regarding polymer types, concentrations, and particle sizes.
  • Manufacturing Process Optimizations: There is continued interest in refining the synthesis of oxybutynin chloride. Patents may cover specific catalysts, solvent systems, purification techniques, or polymorphism control, aiming to improve yield, purity, or reduce production costs.
  • Combinations with Other Active Ingredients: While less common for oxybutynin chloride specifically, some patents might explore its combination with other therapeutic agents for synergistic effects or to address multiple symptoms.

• Implications for Generic Market Entry:

  • Freedom-to-Operate (FTO) Analysis: Generic drug manufacturers must conduct thorough FTO analyses to ensure their proposed product and manufacturing processes do not infringe on existing patents. This is particularly crucial for extended-release formulations and novel manufacturing methods.
  • Patent Litigation: Disputes over patent infringement are common in the pharmaceutical industry. Generic companies often challenge the validity or inventiveness of patents covering formulations or processes, leading to potential litigation.
  • Patent Expiry Dates: The expiry of key formulation patents can open significant opportunities for generic competition, driving down prices and increasing market access. However, it is essential to track the expiry of all relevant patents, including those for specific delivery systems.

What are the Regulatory Considerations for Oxybutynin Chloride?

The manufacturing and marketing of oxybutynin chloride are subject to stringent regulatory oversight by health authorities worldwide. Compliance with these regulations is paramount for API suppliers and finished drug product manufacturers.

• Good Manufacturing Practices (GMP): All manufacturing facilities for oxybutynin chloride API must adhere to current GMP standards. These standards ensure the quality, purity, and consistency of the drug substance. Regulatory bodies like the FDA and EMA conduct regular inspections to verify compliance.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF contains confidential, detailed information about the facilities, processes, and materials used in the manufacturing, processing, packaging, and storing of an API. This allows drug product manufacturers to reference the DMF in their marketing authorization applications without revealing proprietary manufacturing details.
• Quality Control and Testing: Rigorous quality control measures are required at every stage of production. This includes testing for identity, purity, strength, and the absence of impurities. Specifications for oxybutynin chloride are typically defined by pharmacopoeias such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.).
• Impurity Profiling: Regulatory agencies pay close attention to the impurity profile of APIs. Manufacturers must identify, quantify, and control potential impurities, including process-related impurities and degradation products, to ensure patient safety.
• ANDA and NDA Filings: Companies seeking to market generic oxybutynin chloride products must submit an Abbreviated New Drug Application (ANDA) to the FDA. This application demonstrates the bioequivalence of the generic product to the reference listed drug. Brand-name manufacturers submit New Drug Applications (NDAs).
• Post-Market Surveillance: Manufacturers are responsible for monitoring the safety of their products after they have been approved and are on the market. This includes reporting adverse events and taking appropriate action to address any emerging safety concerns.

How Does the Market for Oxybutynin Chloride Compare to Other Antimuscarinics?

Oxybutynin chloride is one of several antimuscarinic agents available for the treatment of overactive bladder (OAB). Its market position is influenced by its efficacy, side effect profile, cost, and the availability of newer or alternative treatments.

• Key Competitors:

  • Tolterodine: Another widely prescribed antimuscarinic, often seen as a direct competitor.
  • Solifenacin: A more selective M3 receptor antagonist, generally associated with a lower incidence of anticholinergic side effects compared to older agents.
  • Darifenacin: Also a selective M3 receptor antagonist.
  • Fesoterodine: A prodrug that is rapidly converted to the active metabolite 5-hydroxymethyl tolterodine.
  • Trospium Chloride: A quaternary ammonium compound with limited ability to cross the blood-brain barrier, potentially leading to fewer central nervous system side effects.

• Market Dynamics:

  • Efficacy vs. Side Effects: Oxybutynin chloride is generally considered effective, but its use can be limited by anticholinergic side effects, such as dry mouth, constipation, and blurred vision. Newer agents, particularly those with greater receptor selectivity, often aim to mitigate these side effects, potentially capturing market share, especially in patients sensitive to or intolerant of older medications.
  • Cost: As an older, off-patent drug, generic oxybutynin chloride is typically more cost-effective than newer, branded antimuscarinic agents. This makes it an attractive option, particularly in healthcare systems with strict cost controls or for patients without comprehensive insurance coverage.
  • Formulation Innovation: The development of extended-release oxybutynin chloride and transdermal patches has helped to improve its tolerability and convenience, allowing it to remain competitive against newer drugs.
  • Treatment Guidelines: Clinical guidelines for OAB often include multiple antimuscarinic options, with the choice depending on individual patient characteristics, tolerability, and cost. Oxybutynin chloride remains a first-line or second-line therapy in many guidelines due to its established efficacy and affordability.
  • Emerging Therapies: The market also sees competition from non-antimuscarinic treatments for OAB, such as beta-3 adrenergic agonists (e.g., Mirabegron) and Botulinum toxin injections, which offer different mechanisms of action and side effect profiles.

Key Takeaways

• The global supply of oxybutynin chloride API is primarily concentrated among manufacturers in China and India, including Zhejiang NHU, Lianyungang Oriental Pharmaceutical, Prism Pharma, Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories.
• While the core composition of matter patents for oxybutynin chloride have expired, innovation and patent protection persist in areas such as extended-release formulations, transdermal delivery systems, and novel manufacturing processes.
• Generic manufacturers must perform comprehensive freedom-to-operate analyses to navigate the existing patent landscape, particularly concerning specialized formulations.
• Regulatory compliance with GMP, DMF submissions, and rigorous quality control is essential for API suppliers.
• Oxybutynin chloride remains a significant player in the overactive bladder market due to its efficacy and cost-effectiveness, although it faces competition from newer, more selective antimuscarinics and alternative therapeutic classes.

Frequently Asked Questions

1. What is the typical purity requirement for oxybutynin chloride API supplied to regulated markets? Suppliers must meet pharmacopoeial standards, such as USP or Ph. Eur., which specify limits for impurities, usually requiring API purity of 98.5% or higher, with strict controls on specific known and unknown impurities.

2. Are there any current U.S. FDA warning letters outstanding against major oxybutynin chloride API manufacturers? A review of public FDA databases is necessary for the most current information. However, the FDA issues warning letters for GMP non-compliance, which can impact a facility's ability to supply to the U.S. market.

3. What is the typical shelf life for oxybutynin chloride API under recommended storage conditions? The shelf life of an API depends on its stability characteristics and packaging. Manufacturers typically establish retest dates or expiry dates based on stability studies, commonly ranging from two to five years.

4. How does the cost of generic oxybutynin chloride compare to branded versions or newer antimuscarinic drugs? Generic oxybutynin chloride is significantly less expensive than branded formulations and substantially more affordable than newer, patented antimuscarinic agents, making it a preferred choice based on cost.

5. Can a patent for a specific extended-release formulation of oxybutynin chloride prevent the sale of an immediate-release generic version? A patent for an extended-release formulation typically only protects that specific formulation and its method of manufacturing or use. It generally does not prevent the sale of a generic immediate-release version, provided that version does not infringe on other active patents.

---

Citations

[1] Zhejiang NHU Co., Ltd. Corporate Website. (n.d.). Retrieved from [Relevant corporate website section on APIs or company profile] [2] Lianyungang Oriental Pharmaceutical Co., Ltd. Corporate Website. (n.d.). Retrieved from [Relevant corporate website section on APIs or company profile] [3] Prism Pharma Co., Ltd. Corporate Website. (n.d.). Retrieved from [Relevant corporate website section on APIs or company profile] [4] Aurobindo Pharma Ltd. Corporate Website. (n.d.). Retrieved from [Relevant corporate website section on APIs or company profile] [5] Sun Pharmaceutical Industries Ltd. Corporate Website. (n.d.). Retrieved from [Relevant corporate website section on APIs or company profile] [6] Dr. Reddy's Laboratories Ltd. Corporate Website. (n.d.). Retrieved from [Relevant corporate website section on APIs or company profile] [7] United States Patent and Trademark Office (USPTO) Patent Database. (n.d.). Retrieved from [Search query for oxybutynin chloride formulations and manufacturing processes] [8] European Patent Office (EPO) Espacenet Database. (n.d.). Retrieved from [Search query for oxybutynin chloride formulations and manufacturing processes] [9] U.S. Food and Drug Administration (FDA). (n.d.). Guidance for Industry. Retrieved from [Relevant FDA guidance documents on APIs, DMFs, and ANDA submissions] [10] European Medicines Agency (EMA). (n.d.). Scientific Guidelines. Retrieved from [Relevant EMA guidelines on API manufacturing and quality] [11] United States Pharmacopeia (USP). (n.d.). United States Pharmacopeia and National Formulary. [Relevant monograph for Oxybutynin Chloride] [12] European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). European Pharmacopoeia. [Relevant monograph for Oxybutynin Chloride]